Clear ×
Cyclerion Therapeutics, Inc. CYCN

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 11, 2026 8-K 57 signals fired · top 15
Other
Cash Flow Statement Investing Activities Executive Educational Background Disclosure Director Officer Indemnification Provision Lease Rou Incremental Borrowing Rate Disclosure Audit Committee Independence Certification Net Loss Reported Code Of Conduct Adoption Disclosure Effective Tax Rate Reconciliation New York Jurisdiction Clause Employee Director Compensation Waiver Reverse Stock Split Effected Fcpa Compliance Representation Diversity Equity Inclusion Commitment Nyse Listing Disclosure
Core
Management Exodus
Aug 27, 2026 8-K 7 signals fired
Other
Auditor Appointment Ratification Reverse Stock Split Effected Say On Pay Vote Result Disclosed Equity Plan Board Approval Conditional On Shareholder Vote Quorum Presence Disclosed Adjournment Proposal Voting Requirement Nyse Listing Disclosure
Aug 4, 2026 10-Q 14 signals fired
Other
Net Loss Reported Liquidity Position Snapshot Disclosed Cash Flow Statement Investing Activities Fair Value Hierarchy Reconciliation Disclosed Stock Option Grant Disclosed Financing Activities Cash Flow Disclosure Institutional Investment Shares Outstanding Disclosure Ipo Or Capital Raising Completion Personnel Cost Decrease Disclosure Interest Income Year Over Year Comparison Burn Rate Controlled Convertible Debt Conversion Rsu Psu Vesting Schedule Disclosed
May 12, 2026 10-Q 22 signals fired · top 15
Other
Net Loss Reported Capital Raising Uncertainty Disclosed Fair Value Hierarchy Reconciliation Disclosed Cash Flow Statement Investing Activities Liquidity Position Snapshot Disclosed Ipo Or Capital Raising Completion Institutional Investment Financing Activities Cash Flow Disclosure Use Of Proceeds Disclosure Shares Outstanding Disclosure Interim Data Positive Reverse Stock Split Effected Fast Track Designation Received
Core
Lead Asset Progress Indication Expansion
Apr 1, 2026 8-K 63 signals fired · top 15
Other
Earnings Call Qa Segment Corporate Organization And Standing Representation Reverse Stock Split Effected Fcpa Compliance Representation Merger Subsidiary Creation Earnings Call Replay Details Share Withholding Tax Settlement Merger Proxy Statement Disclosure Successor Agent Appointment Provision Corporate Authority Representation Market Price Definition Amendment Modification Waiver Clause Registration Rights Piggyback Provision Non Assignment Clause
Core
Clinical Trial Result
Mar 30, 2026 10-K 75 signals fired · top 15
Other
Capital Raising Uncertainty Disclosed Fcpa Compliance Representation Net Loss Reported Patent Family Portfolio Disclosure Confidential Information Return Obligation New York Jurisdiction Clause Institutional Investment Form S3 Shelf Registration Disclosure Shareholder Dilution Warning Nasdaq Minimum Bid Price Delisting Notice Cybersecurity Risk Management Program Disclosure Diversity Equity Inclusion Commitment Nyse Listing Disclosure Termination For Material Breach Clause
Core
Clinical Trial Result